134965-39-2Relevant articles and documents
Synthesis of functionalized pyridazin-3(2 H)-ones via nucleophilic substitution of hydrogen (SNH)
Verhelst, Tom,Verbeeck, Stefan,Ryabtsova, Oxana,Depraetere, Stefaan,Maes, Bert U. W.
supporting information; experimental part, p. 272 - 275 (2011/04/22)
Reaction of 2-benzyl-5-halopyridazin-3(2H)-ones (3) with Grignard reagents followed by quenching with electrophiles unexpectedly yielded 4,5-disubstituted pyridazin-3(2H)-ones instead of 5-substituted pyridazin-3(2H)-ones. These reactions represent the fi
Synthesis of functionalized pyridazin-3(2H)-ones via bromine-magnesium exchange on bromopyridazin-3(2H)-ones
Ryabtsova, Oxana,Verhelst, Tom,Baeten, Mattijs,Vande Velde, Christophe M. L.,Maes, Bert U. W.
supporting information; experimental part, p. 9440 - 9445 (2010/03/24)
(Chemical Equation Presented) The potential of halogen-magnesium exchange reactions, followed by quenching with electrophiles, for the functionalization of the pyridazin-3(2H)-one core was investigated. 2-Benzyl-4-bromo-5-methoxy- (1), 2-benzyl-5-bromo-4-
Azabicyclic heterocycles as cannabinoid receptor modulators
-
Page/Page column 14, (2008/06/13)
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.